Pressure Ulcer Prevention 20110321
HL7 project team meeting, 21 March, 2011, 3:00 PM ET
Back to Pressure Ulcer Prevention
|Patty Greim||Y||Jay Lyle||Y|
|Ioana Singureanu||John Carter|
|Catherine Hoang||Y||Moon-Hee Lee|
|Mimi Haberfeld||Donna DuLong||Y|
|Charlie Selhorst||Y||Sherri Simons||Y|
|You-Ying Whipple||Holly Miller||Y|
|Walter Suarez||Susan Matney||Y|
|Elaine Ayres||Nancy Collins|
- Agenda check
- Ballot status
- Open tasks
- review introduction
- review questions
- review model
No changes to agenda
Ulcer site to be a precoordinated list; we still need sites for devices.
Collapsing circulatory and perfusion issues into one class.
(Surgery was mentioned as a risk factor, neither drug nor condition. Do we need to add it?)
Regarding medication risk, should we capture potential medication effects, or is Braden sufficient? Using medication to predict risk may also require additional information (dose, frequency, weight, etc.) We'll leave this question explicit in the ballot.
Therapeutic class not in RxNorm; may use NDFRT
Is PEG a significant variant of G-tube for our purposes? Leave open in ballot.
Do we need to capture devices related to ulcers if the devices are no longer present? That depends on use of the model: is it purely to identify risk of new ulcers, assess risk of continuation of existing ulcers, or also to document known factors causing existing ulcers? Leave question open in ballot.
Either way, we need to connect the ulcer to the device.
The model will be posted late Monday, and again at least once before it goes to ballot on Sunday. Please forward comments soon if you wish to see them reflected in the ballot.
|12||Review question list; provide feedback to Jay||All||3/21||Open|
|13||Review introduction; provide feedback to Jay||All||3/21||Open|
|11||Determine whether modeling tool can support vocabulary metadata in a readable format||Jay||2/21||Closed||We can use HTML to provide easy reference|
|10||Identify clinical experts we want to review the ballot||Team||2/14||IP|
|9||Send out schedule with model packages assigned to dates; request for team to address specific questions||Jay||2/10||closed|
|3||Confirm workgroup sponsorship from Patient Care or Clinical Interoperability Council or both||Patty and Holly||2/9||closed||Working on scheduling time with Stephen Chu (1/20)
Meeting for 2/9, per Wm Goossen (1/24). Accepted in PC 2/9
|4||Find out from Moon Hee how we can encourage or support more participation||Patty||closed||Time change seemed to work well|
|5||Contact Audrey Dickerson to clarify how IHE specifications relate, affect us||Holly||closed||Met; FSA to be considered in model|
|6||Contact SMEs to coordinate clinical input into the model||Holly||Closed|
|8||Find a better time for this meeting||Jay, Holly||Closed||Moved to 3 pm ET|
|7||Ensure 2/9 PC meeting time is sent to KP participants||Jay||Closed||HL7 info sent 2/1|
|1||please send feedback on the project scope statement||All||1/17||Closed|
|2||meet to clarify the model boundaries||Jay and Donna||1/11||Closed||We recommend that the conceptual scope be “Pressure Ulcer Risk Assessment” and "Intervention," two key focuses of the KP-VA model.|
|2||No official HL7 project sponsor||1/10||Closed||See action item 3, in process (1/12)
PC probably; needs meeting to confirm (1/19); approved 2/9
|1||Model boundaries unclear||1/10||Closed||See action item 2, to be confirmed (1/12)
Clarified in meeting (1/19)